Anticardiolipin antibodies in autoimmune thyroid disease.

J Clin Lab Immunol

Department of Endocrinology, Hospital La Paz, Madrid, Spain.

Published: April 1995

IgG and IgM anticardiolipin antibodies were assayed by an ELISA technique in 69 patients with autoimmune thyroid disease (ATD) and compared with 43 patients with thyroid disease of no autoimmune aetiology (non-ATD) and 72 healthy controls. IgG anticardiolipin antibodies were detectable in 3 of 41 patients with Graves' disease, in 4 of 28 patients with Hashimoto's thyroiditis, in 5 of 43 non-ATD patients and in 3 of 72 normal subjects (differences not significant). IgM antibodies were measurable in 3 patients with Graves' disease, in 1 patient with Hashimoto's thyroiditis, in 1 non-ATD patient and in 2 normal subjects (differences not significant). Patients with anticardiolipin antibodies did not exhibit a higher titre of thyroglobulin or thyroid microsomal antibodies than patients without anticardiolipin antibodies. There was no relation between IgG or IgM anticardiolipin antibody levels and the thyroid function status, the serum concentration of thyroid hormones or thyrotrophin levels. Neither was there any correlation between anticardiolipin antibody levels and age, sex, previous treatments or time of disease progress. Our results suggest that there is no association between anticardiolipin antibodies and ATD.

Download full-text PDF

Source

Publication Analysis

Top Keywords

anticardiolipin antibodies
24
thyroid disease
12
anticardiolipin
8
autoimmune thyroid
8
igg igm
8
igm anticardiolipin
8
patients
8
patients graves'
8
graves' disease
8
hashimoto's thyroiditis
8

Similar Publications

Autoimmune rheumatic manifestations in a cohort of Egyptian COVID-19 patients.

Egypt J Immunol

January 2025

Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

The coronavirus disease 2019 (COVID-19) pandemic had significant global health impact. Like systemic autoimmune diseases, COVID-19 may manifest with systemic and heterogenous clinical presentations. This study aimed to evaluate the prevalence of autoimmune rheumatic manifestations among a cohort of Egyptian patients with COVID-19 infection.

View Article and Find Full Text PDF

Thrombocytopenia is one of the most common manifestations of the antiphospholipid syndrome (APS). However, its causes are still poorly defined. We have shown recently that antiphospholipid antibodies (aPL) directed against β2-glycoprotein I (β2GPI) of the IgG isotype induced platelet activation and aggregation while aPL directed against cardiolipin and anti-β2GPI IgM had no effect.

View Article and Find Full Text PDF

Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.

BMC Med

January 2025

Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.

Background: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.

Methods: In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry.

View Article and Find Full Text PDF

Background: The 2023 American College of Rheumatology and modified Sapporo criteria for antiphospholipid syndrome (APS) recommend ELISA to detect anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GP1) IgG/IgM antibodies, focusing on moderate to high levels or exceeding the 99th percentile. This study aims to establish the 99th percentile threshold for anti-phospholipid (aPL) antibodies and compare the diagnostic accuracies of these thresholds with manufacturer cutoffs using 2 methodologies.

Methods: The 99th percentile cutoffs for aPL antibodies from 305 healthy donors were established using Aptiva, Particle-Based Multi-Analyte Technology (PMAT), and QUANTA Lite (QL) ELISA, following nonparametric reference interval estimation.

View Article and Find Full Text PDF

Positivity of antiphosphatidylserine/prothrombin antibodies identifies a subgroup of more severe antiphospholipid syndrome patients.

Clin Exp Rheumatol

January 2025

Laboratoire d'Immunologie, AP-HP, Hôpital Européen Georges Pompidou, Paris; and Inflammation, Complement, and Cancer, Université Paris Cité, INSERM, UMRS 1138, Cordeliers Research Center, Team Paris, France.

Objectives: Antiphospholipid syndrome (APS) is an autoimmune disease combining the occurrence of thrombotic and/or obstetric events with the persistent presence of antiphospholipid antibodies (i.e. lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti-beta-2-glycoprotein I (aβ2GPI) antibodies).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!